Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
